Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Steinberg MH, et al. Among authors: pegelow ch. JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645. JAMA. 2003. PMID: 12672732 Clinical Trial.
Hydroxyurea and sickle cell anemia: effect on quality of life.
Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Ballas SK, et al. Among authors: pegelow ch. Health Qual Life Outcomes. 2006 Aug 31;4:59. doi: 10.1186/1477-7525-4-59. Health Qual Life Outcomes. 2006. PMID: 16942629 Free PMC article. Clinical Trial.
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Smith WR, et al. Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11. Pain Med. 2011. PMID: 21481164 Free PMC article. Clinical Trial.
Nesidioblastosis in sickle cell disease.
Culberson DE, Manci EA, Shah AK, Haynes J, Ballas SK, Pegelow C, Vichinsky E. Culberson DE, et al. Pediatr Pathol Mol Med. 2001 Mar-Apr;20(2):155-65. doi: 10.1080/15513810109168608. Pediatr Pathol Mol Med. 2001. PMID: 12673839
Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia.
Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Hsu LL, et al. Among authors: pegelow ch. J Pediatr Hematol Oncol. 2003 Aug;25(8):622-8. doi: 10.1097/00043426-200308000-00007. J Pediatr Hematol Oncol. 2003. PMID: 12902915
Stroke prevention trial in sickle cell anemia.
Adams RJ, McKie VC, Brambilla D, Carl E, Gallagher D, Nichols FT, Roach S, Abboud M, Berman B, Driscoll C, Files B, Hsu L, Hurlet A, Miller S, Olivieri N, Pegelow C, Scher C, Vichinsky E, Wang W, Woods G, Kutlar A, Wright E, Hagner S, Tighe F, Waclawiw MA, et al. Adams RJ, et al. Control Clin Trials. 1998 Feb;19(1):110-29. doi: 10.1016/s0197-2456(97)00099-8. Control Clin Trials. 1998. PMID: 9492971 Free article. Clinical Trial.
80 results